CeriBell (NASDAQ:CBLL) Coverage Initiated at TD Cowen

TD Cowen initiated coverage on shares of CeriBell (NASDAQ:CBLLFree Report) in a report released on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $31.00 price objective on the stock.

Separately, William Blair started coverage on CeriBell in a report on Tuesday. They set an “outperform” rating on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $31.00.

Get Our Latest Report on CeriBell

CeriBell Price Performance

NASDAQ:CBLL opened at $26.96 on Tuesday. CeriBell has a 12 month low of $23.00 and a 12 month high of $27.71.

CeriBell Company Profile

(Get Free Report)

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

See Also

Analyst Recommendations for CeriBell (NASDAQ:CBLL)

Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.